Hamilton James C, Chief Discovery/Trans Medicine officer, has demonstrated a consistent pattern of selling shares in Arrowhead Pharmaceuticals (ARWR) over the past two years, with no recorded purchases. According to SEC Form 4 filings, his 28 reported transactions since early 2024 have exclusively involved sales, totaling approximately $7.34 million. The most recent activity includes a $641,900 sale on March 5, 2026, following a concentrated series of disposals earlier in the year—notably on January 5, 2026, when seven separate transactions ranged from $21,012 to $932,043.92.
The selling trend has been persistent, with notable transactions including a $700,000 sale in October 2025 and a $450,000 disposal in September of that year. Smaller but frequent sales, such as the $122,220 in August 2025 and multiple January 2024 transactions totaling over $1.3 million, suggest a recurring divestment strategy rather than a one-time liquidation. The absence of any buy transactions—coupled with multiple awards (coded "A") with no reported value—indicates that Hamilton has been reducing his position in ARWR without acquiring additional shares. The scale and consistency of these sales highlight a clear directional bias toward decreasing his holdings in the company.
AI-assisted summary